An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma-Reference-Cited by-同舟云学术

An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

Published:2019-11-18 Issue:1 Volume:21 Page:29-38
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Morabito Fortunato¹²,Recchia Anna Grazia²,Vigna Ernesto²³,Botta Cirino²³,Skafi Mamdouh¹,Abu-Rayyan Mohammed¹,Atrash Moien¹,Galimberti Sara⁴,Morabito Lucio⁵,Al-Janazreh Hamdi¹,Martino Massimo⁶^ORCID,Cutrona Giovanna⁷,Gentile Massimo²³

Affiliation:

1. Hematology Department and Bone Marrow Transplant Unit, Cancer Care Center, Augusta Victoria Hospital, East Jerusalem, Israel

2. Hematology and Oncology Department, Biotechnology Research Unit, Cosenza, Italy

3. Hematology and Oncology Department, Hematology Unit, Cosenza, Italy

4. Section of Hematology, University of Pisa, Pisa, Italy

5. Humanitas Clinical and Research Center – IRCCS, Humanitas Cancer Center, Milan, Italy

6. Stem Cell Transplant Program, Clinical Section, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio, Italy

7. Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy

Funder

funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2019.1689959

Reference95 articles.

1. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

2. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

3. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome

4. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

5. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes;Frontiers in Cell and Developmental Biology;2021-08-13

2. The safety of available chemo-free treatments for mantle cell lymphoma;Expert Opinion on Drug Safety;2020-10-05

3. Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors;American Journal of Clinical Dermatology;2020-07-01